These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6782615)

  • 1. Drug-induced stimulus control and the concept of breaking point: LSD and quipazine.
    Winter JC
    Psychopharmacology (Berl); 1981; 72(2):217-8. PubMed ID: 6782615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure.
    Callahan PM; Appel JB
    Psychopharmacology (Berl); 1990; 100(1):13-8. PubMed ID: 2296621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of quipazine and LSD on monoamines in the rat striatum.
    Miśkiewicz M; Rokosz-Pelc A; Vetulani J
    Pol J Pharmacol Pharm; 1979; 31(5):489-92. PubMed ID: 94944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head twitches induced by LSD and quipazine: similarities and differences.
    Vetulani J; Bednarczyk B; Reichenberg K; Rokosz A
    Neuropharmacology; 1980 Feb; 19(2):155-8. PubMed ID: 6244515
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo evidence of partial agonist activity exerted by purported 5-hydroxytryptamine antagonists.
    Colpaert FC; Niemegeers CJ; Janssen PA
    Eur J Pharmacol; 1979 Oct; 58(4):505-9. PubMed ID: 510385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
    Friedman RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The actions of neuroleptic drugs and putative serotonin receptor antagonists on LSD and quipazine-induced reductions of brain 5-HIAA concentrations.
    Jacoby JH; Poulakos JJ
    J Pharm Pharmacol; 1977 Dec; 29(12):771-3. PubMed ID: 22629
    [No Abstract]   [Full Text] [Related]  

  • 8. Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD.
    Cunningham KA; Callahan PM; Appel JB
    Eur J Pharmacol; 1985 Jan; 108(2):179-86. PubMed ID: 3156756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone alters the effects of LSD, DOM and quipazine on operant behavior of rats.
    Mokler DJ; Commissaris RL; Henck JW; Rech RH
    Pharmacol Biochem Behav; 1984 Sep; 21(3):333-7. PubMed ID: 6593750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verapamil does not antagonize LSD-induced stimulus control.
    Winter JC
    Pharmacol Biochem Behav; 1986 Jul; 25(1):227-8. PubMed ID: 3749230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions.
    White FJ; Appel JB
    Science; 1982 Apr; 216(4545):535-7. PubMed ID: 7071600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus.
    Winter JC
    Psychopharmacology (Berl); 1980; 68(2):159-62. PubMed ID: 6776559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quipazine-induced stimulus control in the rat.
    Winter JC
    Psychopharmacology (Berl); 1979 Feb; 60(3):265-9. PubMed ID: 108704
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of quipazine on pre- and postsynaptic serotonin receptors: single cell studies in the rat CNS.
    Blier P; de Montigny C
    Neuropharmacology; 1983 Apr; 22(4):495-9. PubMed ID: 6856049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.
    Glennon RA; Young R; Rosecrans JA
    Eur J Pharmacol; 1983 Jul; 91(2-3):189-96. PubMed ID: 6617740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists.
    Mokler DJ; Commissaris RL; Warner MR; Rech RH
    J Pharmacol Exp Ther; 1983 Dec; 227(3):557-62. PubMed ID: 6655557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The stimulus properties of para-methoxyamphetamine: a nonessential serotonergic component.
    Winter JC
    Pharmacol Biochem Behav; 1984 Feb; 20(2):201-3. PubMed ID: 6546992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD).
    Cunningham KA; Appel JB
    Psychopharmacology (Berl); 1987; 91(1):67-73. PubMed ID: 3103161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist.
    Colpaert FC; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):206-14. PubMed ID: 7062283
    [No Abstract]   [Full Text] [Related]  

  • 20. Clozapine blocks disruptive and discriminative stimulus effects of quipazine.
    Friedman RL; Sanders-Bush E; Barrett RL
    Eur J Pharmacol; 1984 Oct; 106(1):191-3. PubMed ID: 6529966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.